GD3s-mediated lipid metabolism reprograming promotes proliferation and metastasis of melanoma Authors: Jinyi Liu, Xiaoxue Li, Wan Li, Hong Yang, Xiangjin Zheng, Sha Li, Yihui Yang, Yizhi Zhang, Guanhua Du, Yumin Wang, Jinhua Wang Published: 2026 ABSTRACT AbstractBackgroundMelanoma is an aggressive malignant tumor with an increasing incidence worldwide. Ganglioside GD3 is recognized as a human melanoma-specific antigen and is highly expressed in melanoma tissues and cell lines. GD3 synthase (GD3s) is the rate-limiting enzyme for the synthesis of GD3. However, the function and mechanism of GD3s in melanoma remains poorly understood.MethodsThe expression of GD3s was evaluated by an in silico analysis and detected by melanoma tissue microarray. Cell loss-of-function and gain-of-function, proliferation, colony formation, wound healing assay, transwell assay, tumor xenograft mouse model and a tail vein-injection mouse model were conducted to determine the functional role of GD3s in melanoma progression. Proteomic analysis and metabolomic analysis were used to identify downstream targets of GD3s. Quantification of triglyceride and cholesterol, nile red staining, Western blot, Real-time quantitative PCR (RT-qPCR) and Co-immunoprecipitation (Co-IP) assays were employed to validate the underlying mechanisms of GD3s which aggravate progression of melanoma. High-throughput screening method was used to identify the inhibitor of GD3s.ResultsDysregulated high levels of GD3s were correlated with advanced clinical stages and poor prognoses of melanoma. GD3s promoted the proliferation and metastasis of melanoma by reprograming lipid metabolism. GD3s induced extensive lipid accumulation and elevated expression levels of lipogenic enzymes in melanoma cells by regulating AMPK/SREBP1 signaling pathway. ENMD-2076 L-(+)-Tartaric acid was considered to be a novel GD3s inhibitor and exhibited good anti-tumor activity both in vivo and in vitro. Mechanistically, consistent with shRNA-mediated silencing of GD3s, ENMD-2076 L-(+)-Tartaric acid inhibited de novo fatty acid synthesis through AMPK/SREBP1 pathway.ConclusionsThe current findings uncovered a novel mechanism by which GD3s modulated aberrant lipid metabolism and promoted the progression of melanoma. ENMD-2076 L-(+)-Tartaric acid was firstly discovered as a new inhibitor of GD3s and had good anti-tumor effect both in vitro and in vivo.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12967-026-08191-1.Keywords: Melanoma, GD3s, Lipid metabolism, SREBP1, Drug screening Background Melanoma is an aggressive malignant tumor arising from pigment cells-melanocytes with increasing incidence worldwide [1, 2]. Melanoma accounts for only a small proportion (3%) of skin cancers diagnosed each year, but is accountable for the vast majorty of deaths (65%) [3]. Although significant progress has been made in the targeted therapy of melanoma over the past decade, a majority of patients do not show a lasting response to these treatments [4]. Thus, it is very necessary to develop new therapeutic targets to improve the treatment efficacy of melanoma. Gangliosides, glycosphingolipids containing sialic acid, are components of the plasma membrane of vertebrate cells [5]. Ganglioside GD3 and GD2, are highly expressed in neuroectoderm-derived tumors, including melanoma cells, and play a key role in the formation and progression of tumors. Therefore, GD3 and GD2 have been studied as tumor markers [6]. GD3 acts as a human melanoma-specific antigen and is expressed in most human melanoma tissues and cell lines, although normal melanocytes scarcely express GD3 [6]. GD3 synthase (GD3s, also referred to as ST8SIA1) is the only enzyme responsible for the biosynthesis of GD3 and GD2. Recent studies have shown that GD3s is highly expressed in a variety of cancers and plays an important role in the development of cancers [7–11]. Our previous study also demonstrated epigenetic hypomethylation and upregulation of GD3s in triple-negative breast cancer [12]. In melanoma, GD3s is the rate-limiting enzyme for the synthesis of melanoma-specific antigen GD3. Accordingly, GD3s is reported to be specifically expressed in melanoma cell lines [13]. However, the mechanism by which GD3s promotes melanoma tumorigenesis remains unclear. Given the crucial role of GD3s in melanoma tumorigenesis, there is an urgent need to identify the function of GD3s in melanoma, elucidate its mechanism and find small molecule inhibitors of GD3s. In this study, we systematically explored the role of GD3s in the development and progression of melanoma and demonstrated that GD3s promoted the proliferation and metastasis of melanoma in vivo and in vitro. Mechanistically, by using proteomics and metabolomics multi-omic analysis, we found that GD3s was involved in activating de novo lipogenesis via directly binding to SREBP1 or indirectly regulating AMPK/SREBP1 signaling pathway. High-throughput drug screening model for GD3s inhibitor was established based on GD3s enzymatic reaction and discovered ENMD-2076 L-(+)-Tartaric acid, a new inhibitor that can directly inhibit the activity of GD3s enzyme. We further evaluated the anti-melanoma efficacy of ENMD-2076 L-(+)-Tartaric acid and found that it had good anti-tumor activity. All these results showed that GD3s may be a potential drug target for melanoma and ENMD-2076 L-(+)-Tartaric acid may be used for treatment of melanoma. Materials and methods Bioinformatics analysis Expression of GD3s in melanoma and other cancers was checked by the the GEPIA database (http://gepia.cancer-pku.cn/) and oncomine database (https://www.oncomine.com/). A total of 436 melanoma specimens were collected from TCGA database and the survival of melanoma patients was plotted by https://www.bioinformatics.com.cn, an online platform for data analysis and visualization. The datasets of tumor patients came from TCGA data, and the dataset of normal control came from TCGA normal and GTEx data. Cell culture Human melanoma cell lines M14, OCM-1A and WM451 were purchased from the GuangZhou Jennio Biotech Co., Ltd. (Guangdong, China). The cells were cultured in a humidified incubator containing 5% CO2 at 37 °C and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (0.1 µg/mL of penicillin and 0.1 µg/mL of streptomycin). Establishment of stable cell lines WM451 and M14 cells were cultured in 60 mm dishes to 70% confluence before transfection. WM451 cells were transfected with GD3s-GFP lentiviral particles (Hanbio Biotechnology, Shanghai, China) for 24 h before detection. M14 cells were transfected with specific GD3s shRNA lentivirus (Hanbio Biotechnology, Shanghai, China) for 48 h before detection. Stable transfected cells with high GD3s expression (WM451-GD3s) and corresponding controls (WM451-NC) were selected by incubation with 2 mg/mL puromycin for 4 weeks. The stable low GD3s expression (M14-shGD3s) cell lines and corresponding controls (M14-NC) were selected by incubation with 2 mg/mL puromycin for 3 weeks. Western blot and RT-qPCR were used to verify GD3s expression. Immunohistochemistry (IHC) Melanoma tissues and normal skin tissues were provided by John Wayne Cancer Institute, including 12 cases of normal skin tissues and 43 cases of melanoma tissues. Immunohistochemistry was performed as described previously [14]. The melanoma tissues and normal skin tissues slices were incubated with GD3s antibody (1:200, 24918-1-AP, ProteinTech, USA) and statistically analyzed according to the IHC staining intensity. Cell proliferation and soft agar colony formation assay Cell proliferation was detected by CCK-8 (Beyotime, China) assay according to the manufacturer’s instructions. Cell DNA synthesis was detected by EdU (RiboBio, Guangzhou, China) assay according to the manufacturer’s instructions. The soft agar colony formation assay was carried out in 6-well plate as described previously [15]. Migration and invasion assay Migration and invasion assays were carried out using a transwell apparatus (Corning, NY, USA) with an 8 μm pore polycarbonate membrane insert and performed as described previously [14]. Wound healing assay Cells were cultured in 6-well plate to 90% confluence. An artificial wound was made in cell monolayer and the medium with 1% FBS was replaced. The wound closure was observed and photographed after 24 h. Proteomic analysis by liquid chromatography mass spectrometry (LC-MS/MS) WM451-NC and WM451-GD3s cells were lysed and trypsin digested according to the manufacturer’s instructions. After trypsin digestion, peptide was desalted by Strata X C18 SPE column (Phenomenex) and vacuum-dried. Peptide was reconstituted in 0.5 M TEAB and processed according to the manufacturer’s protocol for TMT kit. All peptide samples were separated and analyzed by EASY-nLC 1000 UPLC system (Thermo Scientific) coupled to an Q Exactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific). The resulting MS/MS data were processed using Maxquant search engine (v.1.5.2.8). Tandem mass spectra were searched against human uniprot database concatenated with reverse decoy database. Protein expression level was calculated by the sum of peak intensities (normalized by the number of theoretically observable peptides) of all peptides matching to the corresponding protein. A volcano plot was constructed to better visualize and identify the differentially expressed proteins between groups. Gene ontology (GO) and KEGG enrichment analysis were performed to characterize these proteins using DAVID website and visualized using the Weishengxin online platform. Metabolomic analysis by Gas Chromatography Time-Of-Flight Mass Spectrometry (GC-TOF/MS) WM451-NC and WM451-GD3s cells were prepared and the cellular metabolic profiling was carried out on GC-TOF/MS (Pegasus HT system, Leco Corporation). The acquired MS files from GC-TOF/MS analysis were exported in the NetCDF format using ChromaTOF software (v3.30; Leco, Los Angeles, CA). CDF files were extracted using custom scripts (revised Matlab toolbox HDA) in the MATLAB 7.1 (The MathWorks, Natick, MA) for data pretreatment procedu res. Statistical analysis was performed mainly using SPSS (SPSS, Chicago, IL) and SIMCA-P 13.0 (Umetrics, Umea, Sweden). Principal component analysis (PCA) as well as orthogonal partial least-squares discriminant analysis (OPLS − DA) were performed to visualize the metabolic differences among the PTC, BTA, and LSCC groups. Metabolites were analyzed by metabolic pathway enrichment, such as glycolysis, amino acid metabolism and fatty acid metabolism. The acquired raw data were analyzed using XploreMET (version 3.0; Metabo-Profile, Shanghai, China). Quantification of free fatty acid, triglyceride and cholesterol Concentration of intracellular free fatty acid was checked using Amplex Red Free Fatty Acid Assay Kit (Beyotime, China) according to the manufacturer’s recommended protocol. Concentration of intracellular triglyceride was checked using triglycerides kit (Biosino, Beijing, China) according to the manufacturer’s recommended protocol. Concentration of cholesterol was checked using total cholesterol kit (Solarbio, Beijing, China) according to the manufacturer’s recommended protocol. Nile red staining To visualize neutral lipid, cells were cultured in the 6-well plates for 24 h, washed in 1X PBS prior to staining with 5 µg/mL Nile red solution (MCE, USA) for 15 min. Samples were then washed with PBS for twice, then stained with Hoechst 33,342. The images were visualized by immunofluorescence microscopy. Real-time quantitative PCR (RT-qPCR) Total RNA (1 µg) was extracted from melanoma cell lines and used for cDNA synthesis (Monad Biotech, Wuhan, China) according to the manufacturer’s instructions. RT-qPCR was performed using 2X Taq Pro Universal SYBR qPCR Master Mix (Vazyme Biotech, Nanjing, China). The primers used in RT-qPCR were showed in Table S1. GAPDH was used as internal control. Western blot assay For protein preparation, cells were collected and lysed with RIPA (Applygen, Beijing, China) and centrifuged to get the supernatant. Protein concentration was quantified by the BCA method (Beyotime, China). Equal amounts of proteins were separated by SDS-PAGE electrophoresis with 4–20% FuturePAGE (ACE Biotechnology, ET15420LGel) and then transferred onto PVDF membranes (Biorad, 1620177). After blocking with confining liquid (Beyotime, P0023B) for 30 min, the blots were probed with the primary antibodies overnight at 4 °C. After being washed, the blots underwent incubation with the appropriate HRP-linked secondary antibody for 2 h, followed by ECL detection (Millipore, WBKLS0500). The antibodies used in Western blot were showed in Table S2. Co-immunoprecipitation (Co-IP) assay WM451 cells were seeded in 60 mm dishes to 70% confluence and transfected with GD3s plasmid. Cells were harvested, suspended in 600 µL lysis buffer with PMSF for 30 min on ice, then centrifuged at 12,000 × g for 10 min at 4 °C. Supernatants were collected and 1 µg of the corresponding antibody was added to the cell lysate, followed by incubation overnight at 4 °C with slow rotation. 10 µL of protein A/G PLUS agarose (sc-2003, Santa Cruz Biotech, USA) were washed three times with an appropriate volume of lysis buffer, each time by centrifugation at 3,000 rpm for 3 min. The pre-washed protein A/G PLUS agarose were then added to the cell lysate that had been incubated with the antibody overnight, and the mixture was incubated for an additional 2 h in room temperature with slow rotation. After the immunoprecipitation reaction, the sample was centrifuged at 3,000 rpm for 3 min at 4 °C. The supernatant was carefully removed, and the beads were washed five times by centrifugation at 1500 r/min, for 5 min at 4 °C. The supernatants were discarded, the beads were mixed with an equal volume of 2× loading buffer, heated at 100 °C for 5 min. The protein levels of GD3s and SREBP1 were detected by Western blot. In vivo assays for tumor growth and metastasis Female BALB/c nude mice (Six-week-old) were purchased from Vital River Laboratory Animal Technology Company (Beijing, China). All procedures were conducted in accordance with the Institute of Materia Medica, CAMS & PUMC. For in vivo tumor growth assay, M14-NC, and M14-shGD3s cells (1 × 107 cells per mouse) were subcutaneously injected into nude mice and then tumor growth and volume were detected every 4 days using the following equation: tumor volume = (length × width2) / 2. After 4 weeks, the mice were sacrificed and weight of xenografts was examined. For in vivo metastasis assay, cells (0.5 × 107 cells per mouse) were injected into the tail vein of nude mice. After 4 weeks, the mice were sacrificed and neoplasm metastasis was analyzed. Cloning, expression and purification of GD3s The DNA sequence encoding the catalytic domain of human GD3s (Tyr49-Ser356) was cloned into the pCMV3-C-His vector. Then, the recombinant plasmid was transfected into HEK293F cells, where GD3s was expressed with fused polyhistidine tag at C-terminus. Harvest cells by centrifugation and lyse the cell pellet by sonication. Cell debris was separated and removed from the cell lysate by centrifugation, leaving the C-terminal His-tagged GD3s in the supernatant. The supernatant was loaded on a Ni-column (GE Healthcare) pre-equilibrated by PBS buffer for affinity purification. The column was then washed and eluted by PBS buffer containing 30 mM and 100 mM imidazole, respectively. The final elution from Ni-column was concentrated and further purified by gel filtration chromatography using Superdex200(GL). The peak fractions were collected and pooled for subsequent activity detections. High-throughput screening model for inhibitors of GD3s CMP-Sialic Acid was used as the donor, N-Acet-D-lactosamine was used as the receptor, and CD73 was used as a 5 ' -nucleotidase. Under the catalysis of GD3s, the Sialic Acid of CMP-Sialic Acid was transferred to N-Acet-D-lactosamine, and the remaining CMP released a free phosphate Pi under the action of CD73 (CD73 cannot act on CMP-Sialic Acid). Then, the malachite green phosphate detect agent was used to detect the amount of Pi in the solution. In the case of fixed density of CMP-Sialic Acid, N Acet-D-lactosamine and CD73, the amount of Pi generated can reflect the activity of GD3s. According to the catalytic reaction principle of GD3s, an efficient, stable and low-cost activity detection model in vitro was established and optimized for high-throughput screening by using a bioactive compound library (L1700, SelleckChem) contained 2399 compounds. Statistical analysis Three experiments were conducted. Data are presented as mean± standard deviation (SD). Two-group comparisons are analyzed using Student’s t-test. Multi-group comparisons are analyzed using one-way ANOVA. Time-course data are analyzed using two-way ANOVA. Statistical significance was defined as P < 0.05. Results GD3s was highly expressed in melanoma and was associated with prognosis Bioinformatics analyses were performed to explore expression of GD3s in cancers. Results showed that GD3s is expressed in a variety of tissues, including brain, intestine, breast, lung, etc. (Figure S1A). We further analyzed the expression of GD3s in different tumor tissues and found that GD3s expression was higher in some types of cancers than in normal tissues, especially in the skin (Fig. 1A, Figure S1B). Survival analysis showed that the overall survival (OS) of melanoma patients was significantly negatively correlated with the expression of GD3s (Fig. 1B). Results from IHC analysis showed that GD3s expression in melanoma patients was significantly higher than that in normal skin tissues adjacent to melanoma (Fig. 1C). In addition, the higher the malignant degree of melanoma, the higher the expression of GD3s (Fig. 1D). We also checked the expression of GD3s in melanoma cell lines and melanocytes, results showed that the expression of GD3s in melanoma cells was higher than that in melanocytes both in mRNA level and protein level (Figure S1C-D). Taken together, our results demonstrate that GD3s is highly expressed in melanoma, and the expression of GD3s is associated with poor outcomes of melanoma patients. GD3s was highly expressed in melanoma and promoted tumor progression. (A) GD3s was highly expressed in patients with DLBC, LGG and SKCM. The expression of GD3s in tumor and normal tissues was analyzed using website http://gepia.cancer-pku.cn/. The red bars represent tumor tissues and the grey bars represent normal tissues. DLBC: Diffuse Large B-cell Lymphoma; GBM: Glioblastoma Multiforme; LGG: Lower Grade Glioma; SKCM: Skin Cutaneous Melanoma; THYM: Thymoma. (B) The OS of melanoma patients was negatively correlated with GD3s expression. The survival analysis was analyzed using a total of 436 melanoma specimens collected from TCGA database. The top 7% patients with the highest expression of GD3s was defined as the high GD3s expression group (30) and the rest was defined as the low GD3s expression group (406). (C) IHC analysis shows that GD3s was highly expressed in melanoma tissues than in normal skin tissues. (D) IHC analysis shows that the higher the malignant degree of melanoma, the higher the expression of GD3s. (E) Results from CCK-8 assay showed that overexpression of GD3s increased proliferation of WM451 cells. Knockdown of GD3s inhibited proliferation of M14 cells. (F) EdU assay results showed that overexpression of GD3s increased DNA synthesis of WM451 cells. Knockdown of GD3s inhibited DNA synthesis of M14 cells. (G) Results from colony formation assay showed that overexpression of GD3s increased colony formation of WM451 cells. Knockdown of GD3s inhibited colony formation of M14 cells. (H) Results from Transwell assay showed that overexpression of GD3s increased migration and invasion of WM451 cells and knockdown of GD3s inhibited migration and invasion of M14 cells. (I) Images of tumors showed that knockdown of GD3s inhibited the growth of tumors in nude mice. (J) Changes of tumor volume which was measured every 4 days. K. Changes of tumor weight after the mice were sacrificed. L. Bioluminescence images showed that knockdown of GD3s inhibited the incidence of metastasis in nude mice. Mice were imaged in week 2 and week 4. M. Lung metastases were observed by gross and microscopic illustrations after the mice sacrificed at week 4. N. Knockdown of GD3s decreased the number of metastatic focuses in lung. O. Results from H&E staining showed that GD3s knockdown inhibited the lung metastasis and bone metastasis. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. n = 6 for tumor growth experiment, n = 5 for tumor metastasis experiment. * P < 0.05, ** P < 0.01 GD3s promoted proliferation, migration and invasion of melanoma in vitro To explore the potential functions of GD3s in melanoma cell lines, WM451 cells were transfected with GD3s-GFP lentiviral particles and M14 cells were transfected with GD3s shRNA lentiviral particles (Figure S1E). Stable transfected cells were selected by puromycin and verified by RT-qPCR and Western blot (Fig. 1E, Figure S1F). These control cells and stable cells were referred to WM451-NC, WM451-GD3s, M14-NC and M14-shGD3s, respectively. To define the function of GD3s in melanoma cells, proliferation, migration and invasion assays were performed. Results showed that overexpression of GD3s promoted the proliferation and DNA synthesis of WM451 cells, while knockdown of GD3s inhibited the proliferation and DNA synthesis of M14 cells (Fig. 1E-F). Moreover, overexpression of GD3s promoted the colony formation of WM451 cells whereas downregulation of GD3s reduced the ability of colony formation of M14 cells (Fig. 1G). In addition, Transwell assay showed that overexpression of GD3s promoted the migration and invasion of WM451 cells, while knockdown of GD3s showed a completely opposite result (Fig. 1H). In conclusion, these results confirmed that GD3s was involved in regulating the tumorigenicity of melanoma cells. GD3s promoted growth and metastasis of melanoma in vivo To investigate the effect of GD3s on the growth of melanoma in vivo, xenograft model was performed. Results showed that knockdown of GD3s expression remarkably inhibited the growth of tumor (Fig. 1I-K). To check the impact of GD3s-mediated metastasis of melanoma in vivo, metastatic model was performed. Results showed that knockdown of GD3s significantly inhibited the metastasis of melanoma in nude mice (Fig. 1L, Figure S2A). Lungs derived from GD3s knockdown group had significantly fewer metastatic nodules than those from M14-NC cell-injected animals (Fig. 1M-N). The results of H&E staining also showed that lung metastasis was obviously inhibited in GD3s knockdown group (Fig. 1O). We also detected expression of melanoma marker S100B in lung tissue by Western blot and found that the expression of S100B in NC group was higher than that in shGD3s group, which further proved that GD3s regulated lung metastasis of melanoma (Figure S2B). In addition, bone metastasis was observed in some control group mice, but no metastasis was occurred in the GD3s knockdown group (Fig. 1O). Altogether, these results confirmed the in vitro results, showing that GD3s contributed to the growth and metastasis of melanoma. GD3s participated in regulating of fatty acid biosynthesis of melanoma To reveal the mechanism of GD3s in melanoma, proteomics and metabolomics multi-omic analysis were performed. Results from proteomics analysis showed that compared to WM451-NC cells, 921 proteins were up-regulated and 871 proteins were down-regulated in WM451-GD3s cells (|log2FC| ≥1.5 and P value ≤ 0.05) (Fig. 2A). All identified proteins were used for GO and KEGG enrichment analysis, which were performed using DAVID website and visualized using the Weishengxin online platform. KEGG pathway enrichment analysis showed that GD3s was involved in regulation pathway of lipid metabolism including fatty acid biosynthesis and fatty acid metabolism (Fig. 2B-C). Further, metabolomics analysis results indicated that GD3s was participated in the regulation of 23 metabolites (Fig. 2D-F). The differential metabolites included amino acid metabolites, lipid metabolites, carbohydrate metabolites, fatty acid metabolites, organic acid and pyridine (Fig. 2G). Among them, the differential fatty acids were arachidonic acid, dodecanoic acid, pentadecanoic acid, oleic acid, palmitic acid and stearic acid (Fig. 2H). The Small Molecule Pathway Database (SMPDB) was used for pathway enrichment analysis of differential metabolites and fatty acid biosynthesis pathway was enriched (Fig. 2I). Overlapping pathway enrichment analysis were analyzed using Venn diagram. The left circle represented pathways enrichment of differential metabolites. The right circle represented pathways enrichment of differential expressed proteins. The overlapping region fatty acid metablism represented the intersection of pathway associated with differential metabolites and those enriched by differential proteins (Fig. 2J). Based on the above results, we speculated that GD3s may play an important role in regulating of fatty acid biosynthesis. Multi-omics revealed that GD3s was involved in regulating of fatty acid biosynthesis of melanoma. A. Proteomics analysis showed that there were 921 up-regulated proteins and 871 down-regulated proteins in WM451-GD3s cells compared to WM451-NC cells (|log2FC| ≥ 1.5 and P value ≤ 0.05). B-C. GO enrichment in BP (biological process), CC (cellular component), MF (molecular function) and KEGG enrichment analysis of differentially expressed proteins. D-F. Metabolomics analysis results showed that there were 23 differential metabolites in WM451-GD3s cells compared to WM451-NC cells. Metabolites were analyzed by OPLS-DA and univariate methods. The intersection of the differential metabolites obtained from the two methods was taken through the Venn. G. Cluster analysis results showed the differential metabolites included amino acid metabolites, lipid metabolites, carbohydrate metabolites, fatty acid metabolites, organic acid and pyridine. H. The expression of 6 differential fatty acid metabolites in WM451 cells. I. Pathway enrichment analysis of differential metabolites used SMPDB library. J. Multi-omic analysis showed that GD3s participated in regulating of fatty acid biosynthesis of melanoma GD3s promoted de novo lipogenesis and enhanced the expression of lipogenic enzymes To further confirm whether overexpression of GD3s was involved in the regulation of aberrant fatty acid biosynthesis in melanoma cells, we evaluated the effect of GD3s on lipid content. Our results showed that overexpression of GD3s in WM451 cells significantly increased the contents of free fatty acid, triglycerides and cholesterol, while knockdown of GD3s in M14 cells decreased the contents of free fatty acid, triglycerides and cholesterol (Fig. 3A). These results were further supported by cellular staining with the lipophilic dye Nile red, indicating that overexpression of GD3s increased the intracellular level of neutral lipids, whereas knockdown of GD3s decreased the intracellular level of neutral lipids (Fig. 3B). In addition, knockdown of the GD3s expression in WM451-GD3s cells decreased the triglycerides, cholesterol and neutral lipids, while overexpressing of GD3s in M14-shGD3s cells increased the triglycerides, cholesterol and neutral lipids (Figure S3A-D). Collectively, our findings suggest that GD3s was involved in the reprogramming of lipid metabolism. To study the regulatory role of GD3s in de novo fatty acid synthesis, we performed experimental investigations to analyze the expression of key lipogenic enzymes including fatty acid synthase (FASN), ATP citrate lyase (ACLY), and Acyl-CoA synthetase long chain family member 3 (ACSL3). Results showed that the expression of FASN, ACLY and ACSL3 were significantly increased at both mRNA and protein levels in WM451-GD3s cells compared to those in WM451-NC cells. When expression of GD3s was knocked down, the expression of FASN, ACLY and ACSL3 were significantly decreased (Fig. 3C-E). To sum up, GD3s promoted de novo lipogenesis and enhanced the expression of lipogenic enzymes. GD3s promoted de novo lipogenesis and enhanced the expression of lipogenic enzymes. (A) Overexpression of GD3s increased the levels of free fatty acids, triglycerides and cholesterol in WM451 cells. Knockdown of GD3s had the opposite effects in M14 cells. (B) Overexpression of GD3s increased the intracellular contents of neutral lipids in WM451 cells. Knockdown of GD3s had the opposite effects in M14 cells. Cellular neutral lipids were measured by double staining with Nile red and Hoechst 33,342. (C) Overexpression of GD3s increased the expression of FASN, ACLY and ACSL3 at mRNA level in WM451 cells. Knockdown of GD3s had the opposite effects in M14 cells. D-E. Overexpression of GD3s increased the expression of FASN, ACLY and ACSL3 at protein level in WM451 cells. Knockdown of GD3s had the opposite effects in M14 cells. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. * P < 0.05, ** P < 0.01 GD3s promoted proliferation and metastasis of melanoma by activating of SREBP1-dependent lipid metabolism It is well known that lipogenic enzyme genes were commonly trans-activated by sterol regulatory elementary binding proteins (SREBPs), a kind of important enzymes in the regulation of lipid metabolism [16]. To elucidate the molecular mechanism of GD3s-mediated lipid metabolism, we checked the expression levels of SREBPs (SREBP1 and SREBP2) in melanoma cells. Results showed that SREBP1 showed significant regulation at both mRNA and protein levels, while SREBP2 exhibited slight mRNA elevation with no corresponding protein changes (Fig. 4A-B). Results from Western blot also showed an increasing expression level of nuclear SREBP1, suggesting that GD3s might promote nuclear translocation of SREBP1, therefore facilitate the transcriptional activity of SREBP1 in melanoma cells (Fig. 4C). Results of Co-IP indicated that GD3s interacted with SREBP1 (Fig. 4D). Next, we detected the stability of SREBP1 in WM451-NC and WM451-GD3s cells after treated with protein synthesis inhibitor cycloheximide (CHX) for 0 h, 2 h, 4 h, 6 h, 8 h and 12 h. Results showed that SREBP1 half-life was significantly extended in WM451-GD3s cells compared to WM451-NC cells, suggesting that GD3s interaction may stabilize SREBP1 protein (Fig. 4E). We further examined the expression of SREBP1 subtypes SREBP-1a and SREBP-1c, and found that the expression of SREBP-1a and SREBP-1c changed after GD3s overexpression or knockdown (Figure S3E). Among them, SREBP-1c showed more significant changes in mRNA levels, which indicated that SREBP-1c played a major role in the regulation of lipid metabolism. Next, we examined the effect of SREBP1 knockdown on lipid metabolism. We found that silencing of SREBP1 reversed the level of triglycerides, cholesterol and neutral lipids which were up-regulated by GD3s expression in WM451 cells (Fig. 4F-G). At the same time, knockdown of SREBP1 in M14 cells with high expression of GD3s could also lead to a decrease in triglycerides, cholesterol and neutral lipids (Figure S4A-B). Furthermore, overexpression of GD3s up-regulated the expression of lipogenic enzymes FASN, ACLY and ACSL3 which could be reversed by knockdown of SREBP1 expression in WM451 cells (Fig. 4H). GD3s promoted proliferation and metastasis of melanoma by activating of SREBP1-dependent lipid metabolism. (A) Overexpression of GD3s increased the expression of SREBP1 at mRNA level in WM451 cells. Knockdown of GD3s had the opposite effects in M14 cells. (B) Overexpression of GD3s increased the expression of SREBP1 at protein level in WM451 cells. Knockdown of GD3s had the opposite effects in M14 cells. (C) Overexpression of GD3s increased the expression of nuclear SREBP1 in WM451 cells. Knockdown of GD3s had the opposite effects in M14 cells. (D) Co-IP assay showed that GD3s interacted with SREBP1. (E) Expression of SREBP1 protein in WM451-GD3s cells was much higher than that of in WM451-NC after treated with CHX (50 µg/mL) for 0 h, 2 h, 4 h, 6 h, 8 h and 12 h, which indicated that GD3s-SREBP1 interaction may stabilize the SREBP1 protein. (F) Overexpression of GD3S up-regulated triglycerides and cholesterol which could be reversed by knockdown of SREBP1 expression in WM451 cells. (G) Overexpression of GD3S up-regulated neutral lipids which could be reversed by knockdown of SREBP1 expression in WM451 cells. (H) Overexpression of GD3S up-regulated the expression level of lipogenic enzymes FASN, ACLY and ACSL3 which could be reversed by knockdown of SREBP1 expression in WM451 cells. (I) Knockdown of SREBP1 reversed proliferation in WM451-GD3s cells. (J) Knockdown of SREBP1 reversed DNA synthesis in WM451-GD3s cells. K. Knockdown of SREBP1 reversed migration and invasion in WM451-GD3s cells. L. Knockdown of SREBP1 reversed the expression level of migration and invasion-related protein N-cadherin and Vimentin in WM451-GD3s cells. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. * P < 0.05, ** P < 0.01 compared to the NC group, # P < 0.05, ## P < 0.01 compared to the WM451-GD3s group To further elucidate the relationship between lipid metabolic reprogramming and progression of melanoma, the expression of SREBP1 in WM451-GD3s cells was knocked down by SREBP1 siRNA. It was showed that silencing of SREBP1 reversed proliferation and DNA synthesis in WM451-GD3s cells (Fig. 4I-J). Knockdown of SREBP1 also reversed migration and invasion and the expression level of migration and invasion-related protein N-cadherin and Vimentin in WM451-GD3s cells (Fig. 4K-L). Taken together, our findings demonstrated that GD3s promoted proliferation and metastasis of melanoma cells by activating of SREBP1-dependent lipid metabolism. GD3s upregulated the expression of SREBP1 through AMPK pathway Previous studies have shown that the AMPK pathway plays a regulatory part in the cell metabolism, including fatty acid synthesis [22, 23]. Our results demonstrated that GD3s mediated expression of lipogenic enzymes by regulating SREBP1.We hypothesized that GD3s may inhibit phosphorylation of AMPK to activate the SREBP1 and promoted the upregulation of lipogenic enzymes. Results from Western blot analysis demonstrated that the phosphorylation of AMPK (Thr172) was significantly reduced in WM451-GD3s, while knockdown of GD3s expression increased the phosphorylation levels of AMPK (Fig. 5A-B). Furthermore, we found that the level of p-AMPK was dramatically increased in WM451-GD3s cells upon treatment with AMPK agonist, metformin. Meanwhile, SREBP1 and lipogenic enzymes FASN, ACLY, ACSL3 was remarkably decreased as expected (Fig. 5C). On the other hand, AMPK inhibitor compound C decreased the level of p-AMPK in M14-shGD3s and reversed the expression of SREBP1 and lipogenic enzymes FASN, ACLY, ACSL3 (Fig. 5D). In addition, the decreased contents of triglycerides and cholesterol and the intensity of Nile red staining in WM451-GD3s cells treated with metformin was also observed (Fig. 5E, G) and increased contents of triglycerides, cholesterol and the intensity of Nile red staining in M14-shGD3s cells treated by compound C (Fig. 5F, H). Taken together, our results indicated that GD3s was involved in activating de novo lipogenesis by regulating AMPK/SREBP1 signaling pathway. GD3s upregulated the expression of SREBP1 through AMPK pathway. (A) Overexpression of GD3s increased the phosphorylation of AMPK in WM451 cells. (B) Knockdown of GD3s had the opposite effects in M14 cells. (C) Overexpression of GD3S up-regulated the expression level of SREBP1, FASN, ACLY and ACSL3 which could be reversed by AMPK agonist metformin treatment for 48 h in WM451 cells. (D) Knockdown of GD3S down-regulated the expression level of SREBP1, FASN, ACLY and ACSL3 which could be reversed by treatment of AMPK inhibitor compound C for 48 h in M14 cells. (E) Overexpression of GD3S up-regulated triglycerides and cholesterol which could be reversed by treatment of metformin in WM451 cells. (F) Knockdown of GD3S down-regulated triglycerides and cholesterol which could be reversed by treatment of compound C in M14 cells. (G) Overexpression of GD3S up-regulated intracellular contents of neutral lipids which could be reversed by treatment of metformin in WM451 cells. (H) Knockdown of GD3S down-regulated intracellular contents of neutral lipids which could be reversed by treatment of compound C in M14 cells. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. * P < 0.05, ** P < 0.01 compared to the NC group, # P < 0.05, ## P < 0.01 compared to the WM451-GD3s group or M14-shGD3s group A candidate inhibitor of GD3s was screened by high-throughput screening model of GD3s inhibitor Our results demonstrated that GD3s played an important functional role in melanoma and that GD3s was involved in activating de novo lipogenesis via regulating AMPK/SREBP1 signaling pathway, which suggest that GD3s may be a potential drug target in melanoma. To look for suitable small-molecule inhibitors of GD3s, which can be used for clinical and research use, high-throughput screening strategy was developed. Here we cloned, expressed and purified GD3s for activity detections (Figure S5A). We stablished a high-throughput drug screening model basing on GD3s enzymatic reaction (Fig. 6A). A small molecule library comprising 2399 compounds was used to screen inhibitors of GD3s. Among them, 6 compounds reduced the activity of GD3s by at least 50% (Fig. 6B, Figure S5B, Table 1). In dose-response experiments, we found that all of the 6 compounds reduced the activity of GD3s in a dose-dependent manner (Figure S5C). Among them, ENMD-2076 L-(+)-Tartaric acid and Combretastatin A4 showed good anti-tumor effect on melanoma cells (Figure S6A). Considering that ENMD-2076 L-(+)-Tartaric acid had a better dose-effect relationship, it was chosen as a candidate inhibitor of GD3s for additional evaluation. GD3s inhibitor ENMD-2076 L-(+)-Tartaric acid inhibited the proliferation, colony formation, migration and invasion of melanoma in vitro. (A) Schematic of high-throughput drug screening model of GD3S inhibitors. (B) A small molecule library comprising 2399 compounds was used in a high-throughput drug screening assay to discover inhibitors of GD3s. 6 compounds reduced the GD3s by at least 50%. (C) CCK-8 assay results showed that GD3s inhibitor ENMD-2076 L-(+)-Tartaric acid inhibited the proliferation of M14 and OCM-1A cells. (D-E). Soft agar assay results showed that GD3s inhibitor ENMD-2076 L-(+)-Tartaric acid inhibited the colony formation of M14 and OCM-1A cells. (F). CCK-8 assay results showed that ENMD-2076 L-(+)-Tartaric acid was more sensitive to M14 and OCM-1A cells. (G). GD3s knockdown could reverse the inhibitory effect of ENMD-2076 on M14 and OCM-1A cells. (H). Transwell assay results showed that GD3s inhibitor ENMD-2076 L-(+)-Tartaric acid inhibited the migration and invasion of M14 and OCM-1A cells. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 Table 1Drug screening results of GD3s inhibitorsNameInhibition (%)InformationSulindac105.4435Sulindac is a non-steroidal anti-inflammatory agent of the arylalkanoic acid class.Thiamine HCl92.37615Thiamine is a water-soluble vitamin of the B complex, its phosphate derivatives are involved in many cellular processes.Remodelin69.25072Remodelin is a potent acetyl-transferase NAT10 inhibitor.ENMD-2076 L-(+)-Tartaric acid67.79621ENMD-2076 L-(+)-Tartaric acid is the tartaric acid of ENMD-2076, selective activity against Aurora A and Flt3.Combretastatin A460.52789Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin.Atovaquone52.13027Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia. Drug screening results of GD3s inhibitors ENMD-2076 L-(+)-Tartaric acid inhibited the progress of melanoma in vitro and in vivo To evaluate the anti-tumor effect of ENMD-2076 L-(+)-Tartaric acid in melanoma cells, CCK-8 assay and soft agar assay were performed. Results showed that ENMD-2076 L-(+)-Tartaric acid inhibited the proliferation and colony formation in a dose-dependent and time-dependent manner in M14 and OCM-1A cells (Fig. 6C-E). We also compared the anti-tumor activity of ENMD-2076 L-(+)-Tartaric acid with reported GD3s inhibitor triptolide. ENMD-2076 L-(+)-Tartaric acid showed better anti-tumor effect with good dose-effect relationship (Figure S6B). Next, we compared the antitumor activity of ENMD-2076 L-(+)-Tartaric acid in GD3s low expression cell line WM451 and GD3s high expression cell lines M14, OCM-1A. Results showed that ENMD-2076 L-(+)-Tartaric acid was more sensitive to M14 and OCM-1A cells (Fig. 6F). In order to verify whether this sensitivity is mediated by GD3s, we next knocked down GD3s in M14 cells and OCM-1A cells respectively, and found that GD3s knockdown could reverse the inhibitory effect of ENMD-2076 on tumor cells, further indicating that the antitumor effect of ENMD-2076 L-(+)-Tartaric acid was mediated by GD3s inhibition (Fig. 6G, Figure S6C). Additionally, ENMD-2076 L-(+)-Tartaric acid inhibited the migration and invasion in a dose-dependent manner in M14 and OCM-1A cells (Fig. 6H). ENMD-2076 L-(+)-Tartaric acid also exhibited good anti-tumor activity in vivo. As shown in Fig. 7A-D; Table 2, the intragastric administration of ENMD-2076 L-(+)-Tartaric acid significantly reduced tumor volume and weight. No mortality or significant changes in body weight was observed in the ENMD-2076 L-(+)-Tartaric acid-treatment groups compared to control group (Fig. 7E). No significant changes in relative organ weights of vital organs including the heart, liver, spleen, lung and kidney were observed in the ENMD-2076 L-(+)-Tartaric acid-treatment groups compared to control group (Fig. 7F). The integrity of the main solid organs was assessed by HE staining, and there was no obvious induction of detectable toxicity in the ENMD-2076 L-(+)-Tartaric acid-treatment groups compared to control group (Figure S7). No obvious systemic toxicity was observed in physiological blood tests (Fig. 7G). These results indicated that ENMD-2076 L-(+)-Tartaric acid could inhibit growth of the melanoma in vivo with good safety profile. Our previous study has confirmed that GD3s is involved in the regulation of fatty acid metabolism. Therefore, we detected the expression of GD3s and SREBP1 in the tumor tissues by IHC staining. Results showed that the expression of GD3s and SREBP1 were decreased in ENMD-2076 L-(+)-Tartaric acid-treatment which demonstrated that ENMD-2076 L-(+)-Tartaric regulated de novo lipogenesis (Fig. 7H-I). GD3s inhibitor ENMD-2076 L-(+)-Tartaric acid inhibited the growth of melanoma in vivo. (A) Schematic diagram of xenograft mouse model treated with ENMD-2076 L-(+)-Tartaric acid in vivo. (B) Images of tumors showed that ENMD-2076 L-(+)-Tartaric acid inhibited the growth of tumors in nude mice. (C) Changes of tumor volume in each group during the ENMD-2076 L-(+)-Tartaric acid and taxol administration period. (D) Changes of tumor weight in each group after ENMD-2076 L-(+)-Tartaric acid and taxol administration. (E) Changes of body weight in each group during the ENMD-2076 L-(+)-Tartaric acid and taxol administration period. (F) The organ index after ENMD-2076 L-(+)-Tartaric acid and taxol administration. (G) Changes of WBC, RBC, PLT, PCT, NEUT and HGB in each group after ENMD-2076 L-(+)-Tartaric acid and taxol administration. (H-I). The expression of GD3s and SREBP1 in tumor tissues in each group after ENMD-2076 L-(+)-Tartaric acid and taxol administration. WBC: white blood cell count; RBC: red blood cell; PLT: platelet count; PCT: plateletocrit; NEUT: neutrophil ratio. Data represent the mean ± SEM. n = 6. * P < 0.05, ** P < 0.01, *** P < 0.001 Table 2Antitumor activity of ENMD-2076 L-(+)-Tartaric acid in melanoma xenograft mice modelGroupDose / mg ·kg− 1Number (end / start)Tumor weight / gTGI (%)Control-6/61.33 ± 0.16-Tax206/60.77 ± 0.16 ***52ENMD-low206/60.97 ± 0.15 **41ENMD-high606/60.62 ± 0.19***54n = 6, mean ± SD. **P < 0.01, ***P < 0.001 vs. control group. TGI: Tumor growth inhibition Antitumor activity of ENMD-2076 L-(+)-Tartaric acid in melanoma xenograft mice model n = 6, mean ± SD. **P < 0.01, ***P < 0.001 vs. control group. TGI: Tumor growth inhibition ENMD-2076 L-(+)-Tartaric regulated de novo lipogenesis via AMPK/SREBP1 signaling pathway We further examined the regulating role of GD3s inhibitors on lipid metabolism. As shown in Fig. 8A-B, ENMD-2076 L-(+)-Tartaric acid inhibited the levels of triglycerides and cholesterol in a dose-dependent manner. We next knocked down GD3s in M14 cells and OCM-1A cells respectively, and found that GD3s knockdown could reverse the inhibitory effect of ENMD-2076 on the content of triglycerides and cholesterol (Fig. 8C-D). In addition, the intracellular contents of neutral lipids were also decreased by ENMD-2076 L-(+)-Tartaric acid treatment (Fig. 8E). Results from Western blot showed that pharmacological inhibition of GD3s by ENMD-2076 L-(+)-Tartaric acid reduced the expression of FASN, ACLY and ACSL3 (Fig. 8F). We further examined the expression of AMPK and SREBP1, results showed that ENMD-2076 L-(+)-Tartaric acid inhibited the phosphorylation of AMPK (Thr172) and reduced the expression of SREBP1 (Fig. 8G). Taken all, our results demonstrated that ENMD-2076 L-(+)-Tartaric regulated de novo lipogenesis via AMPK/SREBP1 signaling pathway. ENMD-2076 L-(+)-Tartaric acid inhibited de novo lipogenesis of melanoma by regulating AMPK. (A) ENMD-2076 L-(+)-Tartaric acid inhibited the levels of triglycerides in M14 cells and OCM-1A cells. (B) ENMD-2076 L-(+)-Tartaric acid inhibited the levels of cholesterol in M14 cells and OCM-1A cells. (C) GD3s knockdown could reverse the inhibitory effect of ENMD-2076 on the content of triglycerides. (D) GD3s knockdown could reverse the inhibitory effect of ENMD-2076 on the content of cholesterol. (E) ENMD-2076 L-(+)-Tartaric acid inhibited the levels of neutral lipids in M14 cells and OCM-1A cells. F-G. ENMD-2076 L-(+)-Tartaric acid inhibited the expression of FASN, ACLY and ACSL3 through AMPK/SREBP1 pathway in M14 cells and OCM-1A cells. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. * P < 0.05, ** P < 0.01 Discussion Although great breakthroughs have been made, the treatment of melanoma still faces great challenges. Current treatments cannot cure most patients with metastatic melanoma. Many patients have primary or acquired resistance to existing treatments [17, 18]. Therefore, it is particularly important to develop new drug targets for melanoma. Here, we found that GD3s was highly expressed in melanoma compared with normal skin. Overexpression of GD3s promoted growth and metastasis of melanoma both in vitro and in vivo. This study is also the first to reveal that GD3s was involved in activating de novo lipogenesis by regulating AMPK/SREBP1 signaling pathway. In light of these findings, GD3s might be a potential drug target for treatment of melanoma. Reprogramming of cellular metabolism is one of the hallmarks of human cancer [19, 20]. Accumulating evidences showed that metabolic reprogramming in cancer is not limited to glucose metabolism, but also including lipid metabolism [21, 22]. GD3s is the only key enzyme in the biosynthesis of GD3 and GD2, we therefore speculated that GD3s may be closely related to lipid metabolism. In this study, using proteomics and metabolomics multi-omic analysis, we found that GD3s was involved in modulating reprogram of lipid metabolism. Overexpression of GD3s increased the triglyceride, cholesterol and neutral lipid in melanoma cells. Knockdown of GD3s reduced triglyceride, cholesterol and neutral lipid content in melanoma cells. We further found that overexpression of GD3s upregulated the expression of key enzymes of de novo fatty acid synthesis including ACLY, FASN and ACSL3 [23–26]. Elevated expression of lipogenic enzymes depends on the transcription factor SREBP1. SREBP1 promoted transcription activation and elongation of lipogenic enzymes genes [27–29]. AMPK suppressed proteolytic cleavage and nuclear translocation of SREBP1. Inhibition of AMPK resulted in activation of SREBP1 and upregulated lipid synthesis [30, 31]. Here, we found that overexpression of GD3s promotes the expression and nuclear translocation of SREBP1. SREBP1 was also found to be upregulated by GD3s-mediated AMPK inhibition, and was responsible for the expression of FASN, ACLY and ACSL3. Our study demonstrated that GD3s overexpression resulted in a decrease in AMPK Thr172 phosphorylation. However, we cannot definitively determine whether GD3s directly inhibited AMPK phosphorylation or AMPK inhibition resulted from GD3s-induced metabolic changes. GD3s-mediated lipid accumulation may change the cell ATP / AMP ratio, leading to AMP-triggered AMPK activation. The GD3s-SREBP1 interaction, combined with AMPK inhibition, may create a positive feedback loop where protein stabilization reinforced transcriptional upregulation, although the precise transcriptional mechanism requires further investigation. In addition, the functional significance of GD3s-SREBP1 interaction requires further characterization. The interaction may facilitate SREBP1 stabilization or coordinate with AMPK signaling, but we cannot exclude indirect mechanisms or the involvement of additional mediators. Taken all, our findings reveal its novel function in regulating AMPK/SREBP1-mediated lipid metabolism. While our data establish GD3s as a regulator of AMPK/SREBP1-mediated lipid metabolism, we have not definitively distinguished whether these effects are mediated directly by GD3s protein or indirectly through altered GD3/GD2 ganglioside synthesis. As GD3s is best characterized for its role in ganglioside biosynthesis, we cannot exclude the possibility that changes in GD3/GD2 levels contribute to the observed metabolic reprogramming, which warrants future investigation. The understanding of the relationship between lipid metabolic reprogramming and progression of melanoma remains limited. In recent years, many studies have shown that lipid metabolism is closely related to the progression of cancer, especially in cancer metastasis. Recent studies have demonstrated that lipid metabolism is largely reprogramed to meet the growing needs of membrane biogenesis to support the proliferation and survival of cancer cells [16, 32]. The relationship between lipid metabolism and metastasis has also been increasingly characterized. Lipogenic enzymes such as FASN and ACLY have been reported to promote epithelial-mesenchymal transition in cancer cells [26, 33]. FASN and ACLY reduced the expression of E-cadherin and increases the expression of N-cadherin and Vimentin, which is closely related to tumor metastasis [34–36]. Combined with our finding that GD3s promoted growth and metastasis of melanoma both in vitro and in vivo, we propose the hypothesis that GD3s regulates lipid metabolism to promote melanoma proliferation and metastasis. In this study, we elucidated the internal relationship and mechanism between lipid metabolic reprogramming and progression of melanoma, and showed that knockdown of SREBP1 reversed the increased proliferation, DNA synthesis, migration and invasion in GD3s overexpressed-cells. Our results clarified that GD3s promoted proliferation and metastasis of melanoma by activating of SREBP1-dependent lipid metabolism. Given the crucial role of GD3s in melanoma, it is important to identify new molecules inhibitor of GD3s. Triptolide was the only small molecule inhibitor of GD3s that had been reported [8, 11]. However, the mechanism of triptolide was to inhibit the expression of hST8Sia I gene at the transcription level through the suppression of NF-κB activation [11]. There are no reports about inhibitors that directly act on GD3s to inhibit its activity. Here, we firstly established a high-throughput drug screening model basing on GD3s enzymatic reaction and discovered ENMD-2076 L-(+)-Tartaric acid, a new inhibitor that can directly inhibit the activity of GD3s enzyme. ENMD-2076 L- ( + ) -Tartaric acid is a novel small molecule kinase inhibitor that inhibits angiogenesis-related kinases, Aurora kinases and growth factor-related kinases [37–40]. As a multi-target inhibitor, ENMD-2076 has been approved in a number of clinical trials, involving ovarian cancer, hepatocellular carcinoma, triple negative breast cancer and other solid tumors [41–45]. Here, we further evaluated the anti-tumor efficacy of ENMD-2076 L-(+)-Tartaric acid in vivo and in vitro and found that it had good anti-tumor activity in melanoma. Our results suggest that ENMD-2076 L-(+)-Tartaric acid exerts anti-melanoma effects that are at least partially dependent on GD3s expression. Although ENMD-2076 is known to inhibit multiple kinases, our genetic evidence supports a contributory role of GD3s inhibition in mediating its therapeutic activity. However, contributions from its known kinase targets cannot be excluded, particularly at lower and higher concentrations. Future studies with more selective GD3s inhibitors will help dissect these effects. Conclusions In summary, our results confirmed that GD3s promoted the proliferation and metastasis of melanoma by activating de novo fatty acid synthesis through a previously unappreciated SREBP1 regulatory mechanism. We discovered a new inhibitor of GD3s, ENMD-2076 L-(+)-Tartaric acid, and found that it had good anti-melanoma activity both in vivo and in vitro. Mechanistically, consistent with shRNA-mediated silencing of GD3s, ENMD-2076 L-(+)-Tartaric acid inhibited de novo fatty acid synthesis through AMPK/SREBP1 pathway. All in all, our results demonstrated that GD3s may be used as a potential drug target of melanoma. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3: Figure S1. The expression of GD3s in melanocyte and melanoma. A. The median expression (median transcripts per million) of GD3s in tumor (red) and normal (green) samples in bodymap which was analyzed using website GEPIA (Gene Expression Profiling Interactive Analysis). The color intensity represents the relative expression level of GD3s, the deeper the color, the higher the expression level. B. GD3s was highly expressed in melanoma than that in normal skin tissues or other kind of tumors. The expression of GD3s (transcripts per million) in tumor and normal tissues was analyzed using website https://www.oncomine.org/. C. The expression of GD3s in melanocyte and melanoma cells was analyzed by RT-qPCR. D. The expression of GD3s in melanocyte and melanoma cells was checked by Western blot. E. WM451 cells with relative lower levels of GD3s were stably transfected with empty vector (WM451-NC) or GD3s-GFP lentiviral particles (WM451-GD3s) for increasing expression of GD3s. M14 cells with relative higher levels of GD3s were stably transfected with a control shRNA (M14-NC) or GD3s-shRNA lentivirus (M14-shGD3s) for decreasing expression of GD3s. After 72 h lentiviral infection, the infection efficiency was observed under fluorescence microscope. F. The expression of GD3s in WM451-NC, WM451-GD3s, M14-NC and M14-shGD3s cells was analyzed by RT-qPCR. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01. Figure S2. GD3s promoted metastasis of melanoma in vivo. A. Metastatic model was performed and the transfer image in first week was shown. B. The melanoma marker S100B was high-expressed in lung tissues of NC group compared with shGD3s group. Figure S3. GD3s promoted de novo lipogenesis and enhanced the expression of lipogenic enzymes. A. Overexpression of GD3s increased the levels of triglycerides and cholesterol in WM451 cells. Knockdown the expression of GD3s in WM451-GD3s cells decreased the contents of triglycerides and cholesterol. B. Overexpression of GD3s increased the intracellular contents of neutral lipids in WM451 cells. Knockdown the expression of GD3s in WM451-GD3s cells decreased the contents of neutral lipids. Cellular neutral lipids were measured by double staining with Nile red and Hoechst. C. Knockdown of GD3s decreased the triglycerides and cholesterol in M14 cells. Overexpression of GD3s in M14-shGD3s cells increased the triglycerides and cholesterol. D. Knockdown of GD3s decreased the neutral lipids in M14 cells. Overexpression of GD3s in M14-shGD3s cells increased the neutral lipids. Cellular neutral lipids were measured by double staining with Nile red and Hoechst. E. The expression of SREBP-1a and SREBP-1c changed after GD3s overexpression or knockdown in mRNA levels. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01, *** P<0.001. Figure S4. GD3s regulated SREBP1-dependent lipid metabolism. A. Knockdown of SREBP1 in M14 cells decreased the contents of triglycerides, cholesterol. B. Knockdown of SREBP1 in M14 cells decreased the contents of neutral lipids. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01. Figure S5. High-throughput screening of GD3s inhibitors. A. Cloning, expression and purification of GD3s for activity detections. B. The structure of potential GD3S inhibitors. C. All the 6 compounds reduced the activity of GD3s in a dose-dependent manner in secondary screening. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01, *** P<0.001. Figure S6. Pharmacodynamic evaluation in vitro of GD3s inhibitor. A. Pharmacodynamic evaluation of the 6 compounds. Only ENMD-2076 L-(+)-Tartaric acid had good anti-tumor activity in vitro. B. Anti-tumor effect of ENMD-2076 L-(+)-Tartaric acid and triptolide on M14 and OCM-1A cells detected by CCK-8 assay. C. Anti-tumor effect of ENMD-2076 L-(+)-Tartaric acid on GD3s knockdown M14 and OCM-1A cells detected by CCK-8 assay. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01, *** P<0.001. Figure S7. ENMD-2076 L-(+)-Tartaric acid could inhibit growth of the melanoma in vivo with good safety profile. Representative image of the hearts, livers, spleens, lungs and kidneys from the control group, taxol group and ENMD-2076 L-(+)-Tartaric acid-treatment groups that were fixed and stained with H&E. Scale bar = 100 μm. The data were shown as the mean ± SD. Supplementary Material 4 Acknowledgements This work was supported by Beijing Natural Science Foundation (25JL008, 7252202), the 2024 China Industrial Technology Infrastructure Public Service Platform Project (GN2024-31-4700), National Key R&D Program of China (2024YFA0919904) and National Natural Science Foundation of China (82300196), Natural Science Foundation of Chongqing Municipality (CSTB2023NSCQ-MSX0262), Chongqing Young Medical Talents Program (YXQN2025024). Author Contribution JYL: Validation, Investigation, Writing-Original Draft, Funding acquisition. XXL: Validation, Investigation. WL: Methodology. HY: Methodology, Validation, Investigation. XJZ: Investigation. SL: Validation, Investigation. YHY: Validation. YZZ: Validation. GHD: Review & Editing, Supervision. YMW: Review & Editing, Supervision. JHW: Resources, Writing - Review & Editing, Supervision, Funding acquisition. All authors read and approved the final manuscript. Data availability Data will be made available on request. Declarations Ethics approval and consent to participate This work was approved by the Institutional Review Board (IRB) of John Wayne Cancer Institute. All participants provided informed consent prior to the study. The animal study protocol was approved by the Animal Care and Use Committee (ACUC) of Institute of Materia Medica, CAMS & PUMC. The study adhered to the guidelines set by the committee. Conflict of interest The authors declare that there is no conflict of interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Yumin Wang, Email: 721wangym@aliyun.com. Jinhua Wang, Email: wjh@imm.ac.cn. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3: Figure S1. The expression of GD3s in melanocyte and melanoma. A. The median expression (median transcripts per million) of GD3s in tumor (red) and normal (green) samples in bodymap which was analyzed using website GEPIA (Gene Expression Profiling Interactive Analysis). The color intensity represents the relative expression level of GD3s, the deeper the color, the higher the expression level. B. GD3s was highly expressed in melanoma than that in normal skin tissues or other kind of tumors. The expression of GD3s (transcripts per million) in tumor and normal tissues was analyzed using website https://www.oncomine.org/. C. The expression of GD3s in melanocyte and melanoma cells was analyzed by RT-qPCR. D. The expression of GD3s in melanocyte and melanoma cells was checked by Western blot. E. WM451 cells with relative lower levels of GD3s were stably transfected with empty vector (WM451-NC) or GD3s-GFP lentiviral particles (WM451-GD3s) for increasing expression of GD3s. M14 cells with relative higher levels of GD3s were stably transfected with a control shRNA (M14-NC) or GD3s-shRNA lentivirus (M14-shGD3s) for decreasing expression of GD3s. After 72 h lentiviral infection, the infection efficiency was observed under fluorescence microscope. F. The expression of GD3s in WM451-NC, WM451-GD3s, M14-NC and M14-shGD3s cells was analyzed by RT-qPCR. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01. Figure S2. GD3s promoted metastasis of melanoma in vivo. A. Metastatic model was performed and the transfer image in first week was shown. B. The melanoma marker S100B was high-expressed in lung tissues of NC group compared with shGD3s group. Figure S3. GD3s promoted de novo lipogenesis and enhanced the expression of lipogenic enzymes. A. Overexpression of GD3s increased the levels of triglycerides and cholesterol in WM451 cells. Knockdown the expression of GD3s in WM451-GD3s cells decreased the contents of triglycerides and cholesterol. B. Overexpression of GD3s increased the intracellular contents of neutral lipids in WM451 cells. Knockdown the expression of GD3s in WM451-GD3s cells decreased the contents of neutral lipids. Cellular neutral lipids were measured by double staining with Nile red and Hoechst. C. Knockdown of GD3s decreased the triglycerides and cholesterol in M14 cells. Overexpression of GD3s in M14-shGD3s cells increased the triglycerides and cholesterol. D. Knockdown of GD3s decreased the neutral lipids in M14 cells. Overexpression of GD3s in M14-shGD3s cells increased the neutral lipids. Cellular neutral lipids were measured by double staining with Nile red and Hoechst. E. The expression of SREBP-1a and SREBP-1c changed after GD3s overexpression or knockdown in mRNA levels. Scale bar = 100 μm. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01, *** P<0.001. Figure S4. GD3s regulated SREBP1-dependent lipid metabolism. A. Knockdown of SREBP1 in M14 cells decreased the contents of triglycerides, cholesterol. B. Knockdown of SREBP1 in M14 cells decreased the contents of neutral lipids. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01. Figure S5. High-throughput screening of GD3s inhibitors. A. Cloning, expression and purification of GD3s for activity detections. B. The structure of potential GD3S inhibitors. C. All the 6 compounds reduced the activity of GD3s in a dose-dependent manner in secondary screening. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01, *** P<0.001. Figure S6. Pharmacodynamic evaluation in vitro of GD3s inhibitor. A. Pharmacodynamic evaluation of the 6 compounds. Only ENMD-2076 L-(+)-Tartaric acid had good anti-tumor activity in vitro. B. Anti-tumor effect of ENMD-2076 L-(+)-Tartaric acid and triptolide on M14 and OCM-1A cells detected by CCK-8 assay. C. Anti-tumor effect of ENMD-2076 L-(+)-Tartaric acid on GD3s knockdown M14 and OCM-1A cells detected by CCK-8 assay. Data represent the mean ± SD. of three independent experiments. * P<0.05, ** P<0.01, *** P<0.001. Figure S7. ENMD-2076 L-(+)-Tartaric acid could inhibit growth of the melanoma in vivo with good safety profile. Representative image of the hearts, livers, spleens, lungs and kidneys from the control group, taxol group and ENMD-2076 L-(+)-Tartaric acid-treatment groups that were fixed and stained with H&E. Scale bar = 100 μm. The data were shown as the mean ± SD. Supplementary Material 4 Data Availability Statement Data will be made available on request.